Quick Answer
Aura Biosciences, Inc. reported Stockholders Equity of $136.91 million for the year ending 2025.
- Aura Biosciences, Inc. showed a decrease of -9.9% in Stockholders Equity from 2024 to 2025.
- This data is from Aura Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$94.71 million | Q2 2020: -$100.58 million | Q3 2020: -$104.00 million | Q1 2021: -$114.19 million | Q2 2021: -$122.75 million | Q3 2021: -$131.02 million | Q1 2022: $141.09 million | Q2 2022: $129.09 million | Q3 2022: $115.05 million | Q1 2023: $180.26 million | Q2 2023: $166.44 million | Q3 2023: $151.72 million | Q1 2024: $208.78 million | Q2 2024: $191.45 million | Q3 2024: $174.67 million | Q1 2025: $127.97 million | Q2 2025: $174.63 million | Q3 2025: $156.67 million.
- Over the full 7 years of available data (2019 to 2025), Aura Biosciences, Inc.'s Stockholders Equity has grown by 256.6%.
- Historical annual values: Fiscal year 2025: $136.91 million | Fiscal year 2024: $151.97 million | Fiscal year 2023: $225.85 million | Fiscal year 2022: $195.58 million | Fiscal year 2021: $152.32 million | Fiscal year 2020: -$108.71 million | Fiscal year 2019: -$87.41 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: